CN CN
Wknife
Wknife
Single Needle & Local Anesthesia
Local anesthesia with a single needle, no need for electrocardiographic synchronization
Minimally Invasive Tumor Technology
Original Technology, Leading the Frontier
Our Technologies>>
Professor Yao pioneered the theory of tumor electroporation twenty years ago
Globally Recognized
In 2000, Professor Yao Chenguo was the first internationally to propose a novel method for tumor ablation using high-voltage, ultra-short pulsed electric field-induced irreversible electroporation (IRE) and elucidated its underlying bioelectromagnetic mechanisms

In 2004, the first international academic journal paper on killing tumor cells with pulsed electric fields was published in IEEE Transactions on Plasma Science, igniting a research surge in pulsed electric field tumor therapy both domestically and globally

Professor Rubinsky, an internationally renowned electroporation expert from the University of California, Berkeley, followed up with related research and collaborated with AngioDynamics to invest in producing the world's first commercial pulsed electric field tumor therapy device—the Nanoknife.
Products
Products
Our Products>>
News
News
MORE >>
Hangzhou V-Onco Medical Technology Co., Ltd.
ABOUT US
Hangzhou V-Onco Medical Technology Co., Ltd. is a high-tech company driven by clinical needs to innovate medical technology, dedicated to providing optimal medical solutions for clinical practice.

The company's core technology is based on its entirely self-developed irreversible electroporation (IRE) technology.

Irreversible electroporation (IRE) tissue ablation technology offers significant advantages of being non-thermal and selective. It enables complete ablation of lesions while preserving the integrity of adjacent critical ductal structures, making it a cutting-edge tool for achieving "thorough lesion removal with minimal collateral damage." As such, it is recognized as the next-generation tissue ablation technology.

 V-Onco's R&D team is a pioneer and trailblazer in the theory and practice of tumor irreversible electroporation. Since firstly introducing the novel concept of using irreversible electroporation for tumor treatment internationally in 2000, the team has successively proposed and developed three generations of IRE technology, consistently leading the global advancement and iteration of IRE medical products.
200+

Patent Technology

40+

Core Patents

20+

International Patents